HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Influence of Angiotensin II Subtype 2 Receptor (AT(2)R) Antagonist, PD123319, on Cardiovascular Remodelling of Aged Spontaneously Hypertensive Rats during Chronic Angiotensin II Subtype 1 Receptor (AT(1)R) Blockade.

Abstract
Cardiac AT(2)R expression is upregulated in the normal process of aging. In this study we determined the contribution of AT(2)R to chronic antihypertensive and remodelling effects of AT(1)R blockade in aged hypertensive rats. Adult (20 weeks) and senescent (20 months) spontaneously hypertensive rats (SHRs) were treated with either the AT(1)R antagonist, candesartan cilexetil (2 mg/kg/day), the AT(2)R antagonist, PD123319 (10 mg/kg/day), or a combination of the 2 compounds. Mean arterial pressure (MAP) and left ventricular volume were markedly decreased by candesartan cilexetil, however, simultaneous treatment with PD123319 had no additional effect on either parameter. Perivascular fibrosis was significantly reduced by candesartan cilexetil in aged animals only, and this effect was reversed by concomitant PD123319 administration. Vascular hypertrophy was reduced by candesartan cilexetil, and these effects were reversed by simultaneous PD123319. These results suggest that AT(2)R stimulation does not significantly influence the antihypertensive effect of chronic AT(1)R blockade, but plays a role in the regulation of vascular structure. The severe degree of cardiac perivascular fibrosis in senescent animals was regressed by AT(1)R blockade and this effect was reversed by simultaneous AT(2)R inhibition, demonstrating an antifibrotic role of AT(2)R stimulation in the aging hypertensive heart.
AuthorsEmma S Jones, M Jane Black, Robert E Widdop
JournalInternational journal of hypertension (Int J Hypertens) Vol. 2012 Pg. 543062 ( 2012) ISSN: 2090-0392 [Electronic] United States
PMID22500216 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: